Yungjin Pharm KRX:003520KOSPI
영진약품 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked23since Sep 11
In Q2 2026, Yungjin Pharm reported revenue of ₩61.6bn, down 1.5% year on year, and an operating loss of ₩1.5bn. Yungjin Pharm (영진약품) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 1 article. The most common catalyst was contracts & orders (1).
Filing signals Supply contract Swung to loss Screener
Yungjin Pharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩61.6bn | -1.5% | −₩1.5bn margin −2.4% | −₩2.4bn |
| Q1 2026 | ₩63.8bn | -0.5% | −₩1.8bn margin −2.8% | −₩2.3bn |
| Q4 2025 derived | ₩66.8bn | +6.3% | −₩1.1bn margin −1.6% | −₩376m |
| Q3 2025 | ₩60.9bn | -1.9% | ₩4m margin 0.0% | −₩1.2bn |
| Q2 2025 | ₩62.5bn | +0.5% | ₩1.9bn margin 3.0% | ₩339m |
| Q1 2025 | ₩64.1bn | -1.3% | ₩2.6bn margin 4.1% | ₩976m |
| Q4 2024 derived | ₩62.9bn | -2.3% | ₩1.6bn margin 2.5% | −₩967m |
| Q3 2024 | ₩62.0bn | +4.5% | ₩1.3bn margin 2.1% | −₩437m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Yungjin Pharm top stories 2 weeks, by number of outlets
- 1
- 2
Latest Yungjin Pharm news Korean headlines
-
영진약품·세르비에 '디아미크롱' 공동판매 10년…처방액 2.4배 증가
1 more on this story · 1 outlets
- 세르비에·영진약품 ‘디아미크롱’, 공동판매 10년 만에 매출 2.4배 성장메디컬투데이 · Oct 12 15:51
-
영진약품, 佛 아테나와 라세카도트릴 산제 국내 도입 계약
2 more on this story · 2 outlets
- 영진약품, 아테나와 라세카도트릴 산제 도입 계약메디포뉴스 · Oct 8 16:28
- 영진약품, 佛 아테나 ‘라세카도트릴 산제’ 국내 도입의학신문(보사) · Oct 8 17:12
-
영진약품, '라세카도트릴' 산제 도입…소아 설사 치료제 확대
1 more on this story · 1 outlets
- 영진약품, 프랑스서 라세카도트릴 산제 도입…소아 설사 치료제 확대PRESS9 · Oct 8 13:41